Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Paul Raskauskas (NPI 1790744746)

Field	Value
Entity Type	Individual
Organization	Paul Raskauskas
Address	6901 International Center Blvd
City	Ft Myers
State	FL
ZIP	33912
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	March 20, 2006

Payer Source	Total Paid
Medicare	$5.2M
Medicaid	$0

Key Findings

This profile aligns with a retina-focused ophthalmology practice that is highly concentrated in intravitreal pharmacologic therapy and related procedures: J0178 (4K claims, $692 avg paid/claim, $2.8M revenue) and J2777 (46.9K claims, $29 avg paid/claim, $1.4M revenue) are the top drug codes, and 67028 (4K claims, $89 avg paid/claim, $355.1K revenue) is the top procedure code for intravitreal injection. The predominance of anti-VEGF/faricimab injections together with the intravitreal injection procedure code indicates routine, high-frequency injection sessions rather than a referral-only consult model.

Revenue concentration is extreme: the precomputed top 3 Medicare codes by revenue account for 86.6% of this provider's total Medicare revenue. Those three contributors are J0178 (53.4% of Medicare revenue), J2777 (26.3%), and 67028 (6.9%), which signals material dependence on a small set of pharmacologic injection services for Medicare revenue.

Payer mix is effectively single-payer Medicare: the provider reports Total Medicare revenue of $5.2M and has no Medicaid billing on file. For payer strategy and network planning this means Medicare reimbursement performance and utilization patterns will overwhelmingly determine the practice’s financial profile and attractiveness to value-based arrangements.

Competitive standing on national Medicare volumes is strong for key codes: J0178 ranks #71 of 3204 providers nationally (98th percentile; notably above typical national volume), J2777 ranks #122 of 2039 (94th percentile; notably above typical national volume), and 67028 ranks #28 of 4255 (99th percentile; extreme outlier). These ranks indicate the provider is a major national-volume participant for intravitreal injections and is operating well above typical provider volumes for these services.

Ancillary diagnostic and evaluation codes also show unusually high throughput, supporting an integrated, procedure-driven clinic model: 92134 (4.5K claims, $30 avg paid/claim, $133.5K revenue) ranks #87 of 26868 (100th percentile; extreme outlier), and 99213 (1.8K claims, $68 avg paid/claim, $120.6K revenue) ranks #1305 of 457151 (100th percentile; extreme outlier). High imaging and E/M volumes suggest in-office monitoring and follow-up are provided at scale alongside injections.

Use of compounded and unclassified drug codes is notable but secondary to anti-VEGF revenue: J7999 (1.1K claims, $66 avg paid/claim, $72.2K revenue) ranks #44 of 1333 (97th percentile; notably above typical national volume), while J3490 (41 claims, $1187 avg paid/claim, $48.7K revenue) is present at a lower percentile (33th percentile; typical, unremarkable volume). This pattern implies routine use of ancillary pharmaceuticals or compounding services in support of retinal care, but these are not the dominant revenue drivers.

Operational implications visible in the claims mix include high-frequency, procedure-centered throughput (multiple thousands of injection claims for J0178 and 67028) combined with substantial imaging and return-visit E/M volume. For payers and network managers this signals a practice oriented to recurring, procedure-based care pathways and the associated utilization monitoring and capacity considerations.

The provider has an established tenure in Medicare reporting with NPI enumerated 2006-03-20 (~20 years ago), and the lifetime Medicare revenue of $5.2M reflects sustained engagement with the Medicare population. Longevity plus concentrated, high-volume service lines suggests a stable, mature retina practice whose Medicare performance will be the primary indicator for contracting or competitive comparisons.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

13 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	3,980	$690	$2.8M
J2777	Injection, faricimab‑svoa, 0.1 mg	46,860	$30	$1.4M
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	3,990	$90	$355.1K
J2778	Injection, ranibizumab, 0.1 mg	1,150	$180	$206.1K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	4,450	$30	$133.5K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,770	$70	$120.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,030	$90	$91.5K
J7999	Compounded drug, not otherwise classified	1,090	$70	$72.2K
J3490	Unclassified drugs	40	$1,190	$48.7K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	140	$120	$16.7K

Showing 1–10 of 13

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Paul Raskauskas — 5 of 13 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

13 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	10	250	800	$690	$817.6K
J2777	15	170	12,810	$30	$549.2K
J2778	29	110	660	$180	$234.1K
67028	5	300	710	$90	$91.1K
J3490	133	180	70	$280	$87.5K
99214	1,761	32,760	140	$90	$25K
J7999	5	190	130	$70	$16.4K
99213	219	30,010	80	$60	$12K
92235	179	190	50	$100	$12K
92134	13	1,610	110	$30	$11.9K

Showing 1–10 of 13

Related Providers

Other providers that share a Tax Identification Number (TIN) with Paul Raskauskas, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Elia Mavrofrides	FL	Ophthalmology Physician	$6.2M	$240
Keye Wong	FL	Retina Specialist (Ophthalmology) Physician	$4.9M	$0
Thomas Ward	FL	Retina Specialist (Ophthalmology) Physician	$4.7M	$0
Thomas Barnard	FL	Ophthalmology Physician	$4.5M	$6.5K
John Niffenegger	FL	Retina Specialist (Ophthalmology) Physician	$4.4M	$0
Samuel Houston	FL	Ophthalmology Physician	$4.2M	$39.3K
Matthew Cunningham	FL	Ophthalmology Physician	$4M	$1.8K
Elizabeth Richter	FL	Retina Specialist (Ophthalmology) Physician	$3.5M	$0
Jaya Kumar	FL	Ophthalmology Physician	$3.4M	$3K
Abdallah Jeroudi	FL	Ophthalmology Physician	$3.3M	$2.9K

Nearby Providers

Other providers in the same ZIP code as Paul Raskauskas, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Neogenomics Laboratories Inc	FL	Clinical Medical Laboratory	$20.9M	$2.3M
Vip America Of Southwest Florida, LLC	FL	Attendant Care Provider	$0	$11.4M
Lee Memorial Health System	FL	General Acute Care Hospital	$0	$11.1M
Island Coast Pediatrics	FL	Pediatrics Physician	$0	$9.9M
St Marks Surgical Center LLC	FL	Ambulatory Surgical Clinic/Center	$3.3M	$0
Avtar Ghuman	FL	Retina Specialist (Ophthalmology) Physician	$3.3M	$0
Yamil Fourzali Sabbag	FL	Nuclear Medicine Physician	$2.4M	$0
Nisha Warrier	FL	Ophthalmology Physician	$2.2M	$0
Katrina Mears	FL	Retina Specialist (Ophthalmology) Physician	$2M	$0
Paramount Surgery Center, LLC	FL	Ambulatory Surgical Clinic/Center	$1.9M	$0

Paul Raskauskas — Billing Profile & Reimbursement Data

Sign up for Paul Raskauskas — Billing Profile & Reimbursement Data policy alerts

Paul Raskauskas — Billing Profile & Reimbursement Data

Sign up for Paul Raskauskas — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References